{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:42Z","timestamp":1793726082524,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"ICMR\/INSERM Project","award":["INDO\/FRC\/442\/13-IHD"],"award-info":[{"award-number":["INDO\/FRC\/442\/13-IHD"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.imlet.2015.09.013","type":"journal-article","created":{"date-parts":[[2015,10,2]],"date-time":"2015-10-02T08:17:33Z","timestamp":1443773853000},"page":"93-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors"],"prefix":"10.1016","volume":"169","author":[{"given":"Patricia","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrimati","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Lacroix-Desmazes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadeesh","family":"Bayry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srini","family":"Kaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanjaksha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2015.09.013_bib0005","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","article-title":"Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs","volume":"339","author":"Ehrenforth","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2015.09.013_bib0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group","volume":"328","author":"Lusher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2015.09.013_bib0015","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group","volume":"83","author":"Bray","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2015.09.013_bib0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2002-32664","article-title":"Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products","volume":"28","author":"Kreuz","year":"2002","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.imlet.2015.09.013_bib0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2516.2003.00708.x","article-title":"The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A","volume":"9","author":"Lusher","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2516.2006.01360.x","article-title":"Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors","volume":"12","author":"Astermark","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2516.2001.00505.x","article-title":"Development of inhibitors in patients with haemophilia from India","volume":"7","author":"Ghosh","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0040","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1365-2516.2002.00687.x","article-title":"First-time development of FVIII inhibitor in haemophilia patients during the postoperative period","volume":"8","author":"Ghosh","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12016-009-8118-1","article-title":"Immune response to FVIII in haemophilia A: an overview of risk factors","volume":"37","author":"Ghosh","year":"2009","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.imlet.2015.09.013_bib0050","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood-2014-08-535328","article-title":"FVIII inhibitors: pathogenesis and avoidance","volume":"125","author":"Astermark","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2015.09.013_bib0055","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1073\/pnas.89.9.3795","article-title":"Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals","volume":"89","author":"Algiman","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.imlet.2015.09.013_bib0060","first-page":"1","article-title":"Factor VIII inhibitor assays: methodology, shortcomings, and challenges","volume":"2","author":"van Geffen","year":"2009","journal-title":"J. Coagul. Disord."},{"key":"10.1016\/j.imlet.2015.09.013_bib0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2516.2012.02781.x","article-title":"False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies","volume":"18","author":"Sahud","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0070","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/s-0038-1656029","article-title":"Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients","volume":"77","author":"Blanco","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.imlet.2015.09.013_bib0075","first-page":"271","article-title":"A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant","volume":"87","author":"Blanco","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.imlet.2015.09.013_bib0080","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ajh.2830420221","article-title":"Simultaneous occurrence of factor VIIIC inhibitor and lupus anticoagulant","volume":"42","author":"Saxena","year":"1993","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.imlet.2015.09.013_bib0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/1096-8652(200010)65:2<154::AID-AJH11>3.0.CO;2-A","article-title":"Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS)","volume":"65","author":"Triplett","year":"2000","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.imlet.2015.09.013_bib0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.autrev.2010.11.005","article-title":"Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options","volume":"10","author":"Shetty","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.imlet.2015.09.013_bib0095","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2141.2009.08005.x","article-title":"Co-morbidities and quality of life in elderly persons with haemophilia","volume":"148","author":"Franchini","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.imlet.2015.09.013_bib0100","first-page":"612","article-title":"Proceedings: a more uniform measurement of factor VIII inhibitors","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb Diath. Haemorrh."},{"key":"10.1016\/j.imlet.2015.09.013_bib0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitor: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.imlet.2015.09.013_bib0110","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.imlet.2015.09.013_bib0115","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1365-2516.2012.02845.x","article-title":"Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients","volume":"18","author":"Pinto","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/tan.12364","article-title":"The association of HLA-DRB1 and HLA-DQB1 alleles with the development of factor VIII inhibitors in severe haemophilia A patients in India","volume":"84","author":"Pinto","year":"2014","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.imlet.2015.09.013_bib0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bcmd.2014.04.007","article-title":"Analysis of F8 inversions as risk factors for FVIII inhibitor development in Indian severe haemophilia A patients","volume":"53","author":"Pinto","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.imlet.2015.09.013_bib0130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2516.2005.01121.x","article-title":"Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions","volume":"11","author":"Jayandharan","year":"2005","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1365-2257.2000.00316.x","article-title":"A survey of patients with acquired hemophilia in a hemophilia centre over a 28-year period","volume":"22","author":"Yee","year":"2000","journal-title":"Clin. Lab. Haematol."},{"key":"10.1016\/j.imlet.2015.09.013_bib0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650169","article-title":"A survey of 215 non-hemophilic patients with inhibitors to Factor VIII","volume":"45","author":"Green","year":"1981","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.imlet.2015.09.013_bib0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s002770050263","article-title":"Acquired factor VIII inhibitors in nonhemophilic patients","volume":"74","author":"S\u00f6hngen","year":"1997","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.imlet.2015.09.013_bib0150","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2516.2004.01031.x","article-title":"Acquired factor VIII inhibitors in non-hemophilic patients: clinical experience of 15 cases","volume":"10","author":"Huang","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0155","first-page":"47","article-title":"Systemic lupus erythematosus develop seven years after acquisition of acquired hemophilia A in a patient with palindromic rheumatism: a case report","volume":"23","author":"Hsieh","year":"2009","journal-title":"Formosan J. Rheumatol."},{"key":"10.1016\/j.imlet.2015.09.013_bib0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02259.x","article-title":"Genetic markers in acquired hemophilia","volume":"16","author":"Oldenburg","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2516.2008.01976.x","article-title":"HLA genotype in patients with acquired haemophilia A","volume":"16","author":"Pavlova","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","article-title":"Genetic risk factors for inhibitors to factors VIII and IX","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0175","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/jth.12631","article-title":"The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A","volume":"12","author":"Eckhardt","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.imlet.2015.09.013_bib0180","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1111\/hae.12685","article-title":"New associations: INFG and TGFB1 genes and the inhibitor development in severe haemophilia A","volume":"21","author":"de Alencar","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0185","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1515\/cclm-2013-0595","article-title":"A specific and sensitive activated partial thromboplastin time (APTT)-based factor VIII inhibitor screening assay","volume":"52","author":"Pinto","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.imlet.2015.09.013_bib0190","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1365-2516.2009.02034.x","article-title":"Antiphospholipid antibodies in haemophilia patients with severe bleeding tendency: cause, consequence or a consequential cause?","volume":"15","author":"Shetty","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.imlet.2015.09.013_bib0195","first-page":"61","article-title":"Transfusion transmitted diseases in haemophilics from western India","volume":"112","author":"Ghosh","year":"2000","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.imlet.2015.09.013_bib0200","series-title":"eLS","article-title":"Autoimmune disease: pathogenesis","author":"Bellone","year":"2015"},{"key":"10.1016\/j.imlet.2015.09.013_bib0205","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(03)12763-8","article-title":"Chronic synovitis and HLA B27 in patients with severe haemophilia","volume":"361","author":"Ghosh","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2015.09.013_bib0210","first-page":"170","article-title":"A study of autoimmune markers in hepatitis C infection","volume":"113","author":"Agarwal","year":"2001","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.imlet.2015.09.013_bib0215","first-page":"12","article-title":"Correlation of autoimmune reactivity with hepatitis B and C virus (HBV and HCV) infection in histologically proven chronic liver diseases","volume":"20","author":"Shantha","year":"2002","journal-title":"Indian J. Med. Microbiol."},{"key":"10.1016\/j.imlet.2015.09.013_bib0220","first-page":"613","article-title":"High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C","volume":"21","author":"Clifford","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.imlet.2015.09.013_bib0225","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000067277","article-title":"Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators","volume":"109","author":"Pradhan","year":"2003","journal-title":"Acta Haematol."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247815300377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247815300377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T05:37:04Z","timestamp":1567229824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247815300377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":45,"alternative-id":["S0165247815300377"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2015.09.013","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2015.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}